NRBO

NeuroBo Pharmaceuticals, Inc. (NRBO) | Rumor.io

NeuroBo Pharmaceuticals

NRBO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NRBO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Sep 30

NeuroBo Pharmaceuticals (NRBO) announced positive top-line results from Part 1 of its Phase 1 trial for DA-1726 in obesity treatment, showing favorable safety and dose-linear pharmacokinetics.
The trial's Part 2 data is expected in Q1 2025, which may have implications for NRBO's stock price.
NRBO's low float (approximately 8.5M shares) and pre-market price of $3.45 may make it an attractive stock to traders and investors.

Generated by AI

Sentiment

Of the messages about NRBO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +7.94
Bearish	0%	0%	0%	0% -7.94

Bullish· Feb 1

$NRBO has a small float of 24.3M shares, which could lead to a significant price movement.
The company has a strong potential for a squeeze, with a short float of 0.6% and a 82.8% gain in the past.
$NRBO has a promising product in the field of neurology, with a device to regenerate nerves, which could lead to significant growth in the future.

Bearish· Nov 9

$NRBO's recent offering at $3 per share is near 52-week lows, potentially indicating a low float and increasing the likelihood of a short squeeze.
The company's trade management has been criticized, with a return of -0.7R, suggesting poor investment decisions.
$NRBO's short interest is overextended, with a 19M share short attack, a nano float of

Generated by AI

Topics

Of the messages about NRBO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	91.89%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	8.11%

Analysts· Sep 12

Analysts are predicting a stock price target for NRBO.
NRBO stock price has been impacted by a recent spike.
Analysts are providing stock price predictions and targets for NRBO.

Announcements· Feb 1

NeuroBo Pharmaceuticals, Inc. ($NRBO) has announced FDA clearance of an Investigational New Drug (IND) application for DA-1726, a novel treatment for obesity.
DA-1726 is a dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist.
NeuroBo Pharmaceuticals will conduct a Phase 1 clinical trial of DA-1726 for the treatment of obesity, following FDA clearance of the IND application.

Technical Analysis· Nov 9

$NRBO is making a premarket move, potentially gearing up for a break over 1.7 with new support at 1.4.
The stock is forming a megafone pattern, with a potential break up to $2.80 and then long-term resistance at $2.80.
$NRBO is trading in a channel that could bounce back to the 1.90ish area, with a potential gap-fill to $2.16.

Generated by AI

Community

Of the messages about NRBO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	34.75%
Newcomers	0%	0%	0%	65.25%

Regulars· Feb 2

The regulars are focusing on the potential for a short-term sell-off in NRBO, citing the need for official news from the company to sustain the current rally.
The stock has seen a significant increase in trading volume, with 446% above average volume, and is currently down -13.36%.
The regulars are discussing the importance of float and short interest, with float at 24.3M and short interest at 0.6%, and are highlighting the potential for a parabolic move, with a 11.5% rally in the past.

Newcomers· Feb 29

$NRBO has received initial approval to begin clinical trials for its obesity treatment drug DA-1726, with the first site IRB approval obtained.
The stock has surged significantly, with a +75.1% increase, following the approval news, and is showing a strong chart since going public in 2016.
Some traders are taking advantage of the momentum, buying into the stock, while others are looking to trade on the recent promising study announcement and promising results from other companies.

Generated by AI

Also Discussed

Investors talking about NRBO also mention

#	Name	Attention
1	Digital Brands Group, Inc. Common StockDBGI	0%0
2	Kiora Pharmaceuticals Inc.KPRX	0%0
3	Avenue Therapeutics Inc.ATXI	0%new
4	PaxMedica Inc.PXMD	0%0
5	BPTS - Biophytis S.A.	——
6	Nuwellis, Inc.NUWE	0%+0
7	PIXY - ShiftPixy, Inc.	——
8	Comera Life Sciences Holdings Inc.CMRA	0%0
9	Cosmos Health Inc.COSM	0.02%+0.01
10	ComSovereign Holding Corp.COMS	0%new